WASHINGTON, March 10, 2015 /PRNewswire/ -- ImmunoClin Corporation (OTC Markets: IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The Company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders. ImmunoClin Corporation has completed the strategic relocation of its European headquarters from France to the United Kingdom and has established its laboratories at the London Bioscience Innovation Centre (LBIC) in Central London. ImmunoClin's corporate headquarters continue to be based in Washington, DC, USA.
"London is a great international location, attractive for research, development and business, as we continue to progress our strategic growth plan. The Company's relocation will facilitate ImmunoClin's interaction with top public and private research institutions," said Dr. Khadija Benlhassan, Director and Chief Scientific Officer of ImmunoClin Corporation.
LBIC is owned and operated by the Royal Veterinary College, an independent college of the University of London and a world-class veterinary and biomedical research institute.
"It is a pleasure to welcome ImmunoClin to the London Bioscience Innovation Centre. We are just a short walk from St. Pancras International, making it easy to access markets both within the UK and mainland Europe," said Dr. Ken Larkin, Chief Executive of the London BioScience Innovation Centre.
About ImmunoClin Corporation
ImmunoClin Corporation is a healthcare company with principal corporate office located in Washington, D.C., USA and European headquarters and Laboratories in Central London, United Kingdom. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease. ImmunoClin holds multiple patents and trademarks on a global basis.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Dr. Dorothy Bray, Director, President & CEO
J. Scott Munro, CFO
Mobile: +1 778-987-4308